How do you approach treatment for a patient with a biochemical relapse while on maintenance lenalidomide after autologous stem cell transplant for multiple myeloma?
What factors (i.e. timing from transplant, dose, prior therapy) impact your decision?
Community PollStarted
What is your preferred treatment strategy for patients who have confirmed M-protein progression without clinical progression on maintenance lenalidomide after autologous SCT for multiple myeloma?
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · University of Chicago
Answered on
Biochemical relapse (i.e. increase in M-spike or light chains meeting criteria for progression on two occasions without clinical progression) is an indication for starting treatment in my opinion. I have seen some recommend increasing the dose of lenalidomide to 25 mg in the hopes this will bring di...
Join for free or sign in to see the full answer